# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Clara Barton (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI024-SYN-TD
- Date: 1874-03-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week depression treatment review. **S**

## History of present illness

Ms. Barton returns six weeks after starting sertraline 50 mg. She has had four sessions of cognitive behavioral therapy and has kept a daily plan of small tasks and walks. She went back to work three weeks ago on a 25-hour week and has kept to it. Her mood is a little better on most days and she can concentrate on one report at a time, but she still feels flat, tires by mid-afternoon, and sleeps about five and a half hours. She has had no side effects since the first week and has missed no doses. She has had no suicidal thoughts. She has seen two friends each week. **S**

| Element | Detail |
|---|---|
| Interval change | Somewhat better mood and concentration; still flat and tired |
| Psychotherapy | Four CBT sessions; daily activity plan |
| Work | Back three weeks on a 25-hour week |
| Sleep | About five and a half hours |
| Safety | No suicidal thoughts |
| PHQ-9 | 12, down from 18 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by mid-afternoon; appetite improving; weight up 0.6 kg |
| Gastrointestinal | Negative | No nausea, diarrhea, or bleeding |
| Psychiatric | Positive | Mood flat but improving; no suicidal thoughts, elevated mood, or racing thoughts |

3 systems reviewed. **S**

## Current medications

- Sertraline 100 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 50.2 kg; BMI 21.7 kg/m². All vital signs are synthetic.

PHQ-9: 12. All results are synthetic.

## Change since baseline

- PHQ-9: 18 at baseline, 12 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Neatly dressed; more animated than at intake |
| Mental status | Alert; speech normal in rate; mood "better, but not myself"; affect mildly constricted and reactive; thought process linear; no suicidal ideation; insight and judgment good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, recurrent, with partial response at six weeks** (F33.1). PHQ-9 12, down 33 percent from 18: a partial response, short of the 50 percent that defines response, on a well-tolerated dose. Suicide risk remains low. **S**
   - Increase sertraline to 100 mg each morning.
   - Nurse telephone check in two weeks for side effects and safety.
   - Continue weekly CBT.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.
2. **Occupational burnout** (Z73.0). Managing the 25-hour week. **S**
   - Increase to 35 hours a week now and to no more than 45 hours in a month if her mood keeps improving; still no field deployment.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 12, down 33 percent from 18: partial response; dose increased |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors unchanged; safety plan reviewed |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no side effects since the first week |
| Medication safety | Tolerability check two weeks after the dose increase | 2 weeks after each dose change | Due | Nurse telephone check booked for two weeks from today |
| Self-management | Psychotherapy, activity, sleep, work hours, and social contact | Every visit during active treatment | Completed today | Four CBT sessions; 25-hour week; sleep about five and a half hours; friends twice a week |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |

## Goal progress

- Response (PHQ-9 down by at least 50 percent) by twelve weeks. In progress; target 1874-04-14. **S**
- Remission (PHQ-9 below 5) and continuation treatment for at least twelve months after remission. In progress; target 1874-06-16. **S**
- Sleep at least six hours most nights. In progress; target 1874-04-14. **S**
- Phased return to work at no more than 45 hours a week, with no field deployment for at least six months. In progress; target 1874-06-16. **S**
- Time with friends or her faith community at least twice a week. In progress; target 1874-06-16. **S**

## Medication changes

- Stopped: Sertraline 50 mg oral tablet, one tablet by mouth each morning **S**
- Started: Sertraline 100 mg oral tablet, one tablet by mouth each morning **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Nurse telephone check in two weeks; depression review in six weeks. **S**
- Next scheduled visit 1874-04-14: twelve-week depression treatment review. **S**
